- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01243138
Africa and Middle East Cardiovascular Epidemiological Study (ACE)
Prevalence of Cardiovascular Risk Factors in Patients Attending General Practice Clinics in Selected Countries in the Africa and The Middle East Region
Descripción general del estudio
Estado
Condiciones
Descripción detallada
This is a cross-sectional, epidemiological study. In the course of this study, 4,300 persons from general practice, and other non specialist clinics of selected countries of the Africa and Middle East region, will be evaluated for the presence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension. The degree of control of hypertension and dyslipidaemia in those previously diagnosed with these conditions will also be assessed. All medications used for CV risk factor control will also be ascertained.
Patient evaluation will be done by physicians in charge of the selected clinics (who will be trained for case report forms completion) over one visit, through history taking, clinical examination as well as laboratory investigations. Every fifth patient seen on a particular day, fulfilling the inclusion and exclusion criteria would be included in the study.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Dammam, Arabia Saudita
- Pfizer Investigational Site
-
Jeddah, Arabia Saudita
- Pfizer Investigational Site
-
Jeddah 21573, Arabia Saudita
- Pfizer Investigational Site
-
Makkah, Arabia Saudita
- Pfizer Investigational Site
-
Riyadh, Arabia Saudita
- Pfizer Investigational Site
-
Riyadh, Arabia Saudita, 11584
- Pfizer Investigational Site
-
Yanbu, Arabia Saudita
- Pfizer Investigational Site
-
-
-
-
-
Alger, Argelia, 16015
- Pfizer Investigational Site
-
Bejaja, Argelia, 6000
- Pfizer Investigational Site
-
Djelfa, Argelia, 17000
- Pfizer Investigational Site
-
Laghouat, Argelia
- Pfizer Investigational Site
-
M'Sila, Argelia
- Pfizer Investigational Site
-
Relizane, Argelia, 48000
- Pfizer Investigational Site
-
Saida, Argelia, 20000
- Pfizer Investigational Site
-
Tebessa, Argelia
- Pfizer Investigational Site
-
Tlemcen, Argelia, 13000
- Pfizer Investigational Site
-
-
-
-
-
Bafoussam, Camerún
- Pfizer Investigational Site
-
Mbandjock, Camerún
- Pfizer Investigational Site
-
Njombe, Camerún
- Pfizer Investigational Site
-
Soa, Camerún
- Pfizer Investigational Site
-
-
Cite Verte
-
Yaounde, Cite Verte, Camerún
- Pfizer Investigational Site
-
-
Deido
-
Douala, Deido, Camerún
- Pfizer Investigational Site
-
-
-
-
-
Alexandria, Egipto
- Pfizer Investigational Site
-
Cairo, Egipto
- Pfizer Investigational Site
-
Shiben Al Kom, Egipto
- Pfizer Investigational Site
-
Tanta, Egipto
- Pfizer Investigational Site
-
-
-
-
-
Abu Dhabi, Emiratos Árabes Unidos
- Pfizer Investigational Site
-
Al Ain, Emiratos Árabes Unidos
- Pfizer Investigational Site
-
Dubai, Emiratos Árabes Unidos
- Pfizer Investigational Site
-
Ras Al Khaima, Emiratos Árabes Unidos
- Pfizer Investigational Site
-
-
-
-
-
Accra, Ghana
- Pfizer Investigational Site
-
Jachie-Ashanti, Ghana
- Pfizer Investigational Site
-
Kumasi, Ghana
- Pfizer Investigational Site
-
Sogakope V/R, Ghana
- Pfizer Investigational Site
-
Takoradi, Ghana
- Pfizer Investigational Site
-
-
-
-
-
Amman, Jordán
- Pfizer Investigational Site
-
Irbid, Jordán
- Pfizer Investigational Site
-
Salt, Jordán
- Pfizer Investigational Site
-
-
-
-
-
Chongoria, Kenia, 60401
- Pfizer Investigational Site
-
Nairobi, Kenia, 00508
- Pfizer Investigational Site
-
-
-
-
-
Adailiya, Kuwait
- Pfizer Investigational Site
-
Fahaheel, Kuwait
- Pfizer Investigational Site
-
Kuwait, Kuwait
- Pfizer Investigational Site
-
Mishref, Kuwait
- Pfizer Investigational Site
-
Qadesya, Kuwait
- Pfizer Investigational Site
-
Yarmouk, Kuwait
- Pfizer Investigational Site
-
-
-
-
-
Beirut, Líbano
- Pfizer Investigational Site
-
Jbeil, Lebanon, Líbano
- Pfizer Investigational Site
-
Jounieh, Líbano
- Pfizer Investigational Site
-
Tripoli, Líbano
- Pfizer Investigational Site
-
-
-
-
-
Abuja, FCT, Nigeria
- Pfizer Investigational Site
-
Abuja, Garki, Nigeria
- Pfizer Investigational Site
-
Calabar, Nigeria
- Pfizer Investigational Site
-
Enugu, Nigeria
- Pfizer Investigational Site
-
Keffi, Nassarawa, Nigeria
- Pfizer Investigational Site
-
-
-
-
-
Kebemer, Senegal
- Pfizer Investigational Site
-
Kedoungou, Senegal
- Pfizer Investigational Site
-
Saint Louis, Senegal
- Pfizer Investigational Site
-
Ziguinchor, Senegal
- Pfizer Investigational Site
-
-
Nabil Choucair
-
Dakar, Nabil Choucair, Senegal
- Pfizer Investigational Site
-
-
Ouakam
-
Dakar, Ouakam, Senegal
- Pfizer Investigational Site
-
-
-
-
-
Kwa-Zulu Natal, Sudáfrica, 4091
- Pfizer Investigational Site
-
Rondebosch, Sudáfrica, 7700
- Pfizer Investigational Site
-
-
Gauteng
-
Halfway House, Gauteng, Sudáfrica, 1685
- Pfizer Investigational Site
-
-
Kwazulu-natal
-
Sydenham, Durban, Kwazulu-natal, Sudáfrica, 4091
- Pfizer Investigational Site
-
-
Limpopo
-
Mokopane, Limpopo, Sudáfrica, 0600
- Pfizer Investigational Site
-
Sheshego, Limpopo, Sudáfrica, 0742
- Pfizer Investigational Site
-
-
Pretoria
-
Mamelodi East, Pretoria, Sudáfrica, 0122
- Pfizer Investigational Site
-
-
-
-
-
Ariana, Túnez, 2073
- Pfizer Investigational Site
-
Bouficha, Túnez, 4010
- Pfizer Investigational Site
-
Messaadine, Túnez, 4013
- Pfizer Investigational Site
-
Sfax, Túnez, 3013
- Pfizer Investigational Site
-
Tunis, Túnez, 1000
- Pfizer Investigational Site
-
Zaghouan, Túnez, 1100
- Pfizer Investigational Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Adult aged 18 or above
Exclusion Criteria:
- Pregnant women and/or lactating mothers
- Subjects presenting with any life threatening disease/condition
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension
Periodo de tiempo: At the time of the first visit
|
At the time of the first visit
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Compare the prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the urban and rural population.
Periodo de tiempo: At the time of the first visit
|
At the time of the first visit
|
Compare the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the male and female population.
Periodo de tiempo: At the time of the first visit
|
At the time of the first visit
|
Stratifying the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension by age groups.
Periodo de tiempo: At the time of the first visit
|
At the time of the first visit
|
Ascertain the level of blood pressure and lipids' control as per the European Society of Cardiology (ESC) guidelines in patients who have been previously diagnosed as hypertensive or dyslipidaemic.
Periodo de tiempo: At the time of the first visit
|
At the time of the first visit
|
Ascertain the most commonly used medications in those that have been previously diagnosed as diabetic, hypertensive or dyslipidaemic.
Periodo de tiempo: At the time of the first visit
|
At the time of the first visit
|
Colaboradores e Investigadores
Publicaciones y enlaces útiles
Publicaciones Generales
- Hamoui O, Omar MI, Raal FJ, Rashed W, Kane A, Alami M, Abreu P, Mashhoud W, Alsheikh-Ali AA. Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. BMC Cardiovasc Disord. 2019 Mar 15;19(1):61. doi: 10.1186/s12872-019-1034-2.
- Brouri M, Ouadahi N, Nibouche D, Benabbas Y, El Hassar M, Bouraoui S, Abad N, Abreu PC, Ikardouchene L. [Cardiovascular risk factors in Algeria. Analysis of the subgroup from the "Africa/Middle East Cardiovascular Epidemiological" Study]. Ann Cardiol Angeiol (Paris). 2018 Apr;67(2):61-66. doi: 10.1016/j.ancard.2018.01.003. Epub 2018 Mar 9. French.
- Raal FJ, Alsheikh-Ali AA, Omar MI, Rashed W, Hamoui O, Kane A, Alami M, Abreu P, Mashhoud WM. Cardiovascular risk factor burden in Africa and the Middle East across country income categories: a post hoc analysis of the cross-sectional Africa Middle East Cardiovascular Epidemiological (ACE) study. Arch Public Health. 2018 Feb 12;76:15. doi: 10.1186/s13690-018-0257-5. eCollection 2018.
- Ahmed AM, Hersi A, Mashhoud W, Arafah MR, Abreu PC, Al Rowaily MA, Al-Mallah MH. Cardiovascular risk factors burden in Saudi Arabia: The Africa Middle East Cardiovascular Epidemiological (ACE) study. J Saudi Heart Assoc. 2017 Oct;29(4):235-243. doi: 10.1016/j.jsha.2017.03.004. Epub 2017 Mar 14.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- A2581186
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .